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Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency characterized 
by persistent or recurrent skin and mucosal surface infections with Candida species. 
Different gene mutations leading to CMC have been identified. These include various 
heterozygous gain-of-function (GOF) mutations in signal transducer and activator 
of transcription 1 (STAT1) that are not only associated with infections but also with 
autoimmune manifestations. Recently, two STAT1 GOF mutations involving the Src 
homology 2 (SH2) domain have been reported, while so far, over 50 mutations have 
been described mainly in the coiled coil and the DNA-binding domains. Here, we present 
two members of a Dutch family with a novel STAT1 mutation located in the SH2 domain. 
T  lymphocytes of these patients revealed STAT1 hyperphosphorylation and higher 
expression of STAT1 target genes. The clinical picture of CMC in our patients could be 
explained by diminished production of interleukin (IL)-17 and IL-22, cytokines important 
in the protection against fungal infections.
Keywords: chronic mucocutaneous candidiasis, signal transducer and activator of transcription 1, src homology 
2 domain, heterozygous mutation, gain-of-function mutation
Abbreviations: CMC, chronic mucocutaneous candidiasis; anti-dsDNA, anti-double stranded DNA; STAT1, signal transducer 
and activator of transcription 1; SH2, Src homology 2; CMV, cytomegalovirus; ANA, antinuclear antibodies; SSA, Sjögren’s-
syndrome-related antigen A (Ro); CENP-B, centromere protein B; MFI, mean fluorescence intensity; PBMC, peripheral 
blood mononuclear cells; ELISA, enzyme-linked immunosorbent assay; HKCA, heat-killed Candida albicans; PMA, phorbol 
12-myristate 13-acetate; I, ionomycin; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
FIguRe 1 | (a) Family pedigree of patients. Symbols in black indicate individuals with the same genetic defect and arrow signs indicate the patients enrolled in this 
study. (B) Table showing clinical data of all four affected individuals. (C) Sanger DNA sequencing chromatogram of mutated STAT1 gene. (D) Evolutionary 
conservation of p.Val653 among species. (e) Three-dimensional structure of phosphorylated STAT1 protein with the mutation (Val653Ile), the phosphorylation site 
(pTyr701), and the target DNA indicated.
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INtRoDuCtIoN
Patient 1 (II-4) (Figures 1A,B) is a 24-year-old female who pre-
sented at age of 1 with a Streptococcus haemolyticus jaw abscess, 
with recurrent oral and esophageal Candida albicans infections 
from the age of 6 onward and an episode of Staphylococcus aureus 
pneumonia and cytomegalovirus (CMV) pneumonia at age of 
7  years. At age of 8, she developed hypothyroidism, and there 
were serologic signs of celiac disease, without clinical relevance. 
Moreover, additional immunological analysis revealed the pres-
ence of antinuclear antibodies (ANA) in high titer (1:5,120), anti-
Sjögren’s-syndrome-related antigen A (Ro), and anti-centromere 
protein B autoantibodies (anti-CENP-B). At the age of 20, she 
developed autoimmune hemolytic anemia. Over the past years, 
the clinical picture has been dominated by recurrent oral and 
esophageal C. albicans infections for which she was repetitively 
treated with antifungal therapies. To prevent recurrence of 
C. albicans infections, she is currently treated with prophylactic 
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antifungal therapy (fluconazole 200  mg once daily). Moreover, 
she has experienced oral and vaginal ulcers which were found 
negative for bacterial, fungal, and viral microbes as determined by 
culture and/or PCR of oral and vaginal swabs and tissue biopsies 
from vaginal ulcers. Because of these ulcers, which were assumed 
to be autoimmune manifestations related to chronic mucocuta-
neous candidiasis (CMC), various immunosuppressive therapies 
have been initiated over time, including steroids, azathioprine, 
hydroxychloroquine, and mycophenolate mofetil, all with little 
benefit. She has recently started treatment with adalimumab 
[anti-tumor necrosis factor (TNF)-α] 40 mg every other week, 
which resulted in complete resolution of oral and vaginal ulcers 
after three subcutaneous injections. After three months of treat-
ment, there is still no recurrence of oral and/or vaginal ulcers, 
whereas no increased incidence of infectious complications was 
reported while using anti-TNF-α treatment.
Peripheral blood total CD3+ T  lymphocyte numbers 
[1.63 ×  109/l (reference value: 0.7–2.1 ×  109/l)], CD4+ T  lym-
phocyte numbers [0.6 × 109/l (reference value: 0.3–1.4 × 109/l)], 
CD8+ T lymphocyte numbers [0.84 × 109/l (reference value: 0.2–
0.9 × 109/l)], total CD19+ B lymphocyte numbers [0.16 × 109/l 
(reference value: 0.1–0.4 × 109/l)], and CD16+ CD56+ NK cell 
numbers [0.1  ×  109/l (reference value: 0.1–0.4  ×  109/l)] were 
within the normal reference ranges. Immunoglobulin levels were 
also found to be within normal limits [IgG 10.5  g/l (reference 
value: 7.0–16.0 g/l), IgA 1.24 g/l (reference value: 0.76–3.91 g/l), 
and IgM 1.12 g/l (reference value: 0.45–2.30 g/l)]. The patient was 
negative for autoantibodies against interleukin (IL)-17A, IL-17F, 
and IL-22. After immunization with a polysaccharide vaccine 
against Streptococcus pneumonia (Pneumovax), IgG antibody 
concentration to all 16 serotypes (1, 3, 4, 5, 6B, 7F, 8, 9V, 14, 15B, 
18C, 19A, 19F, 20, 23F, and 33F) measured increased when com-
pared to pre-vaccination concentrations and for 12 serotypes the 
post-immunization concentrations reached values above 1 μg/
ml, which is indicative of a normal response to polysaccharide 
immunization (1).
Patient 2 (I-1) (Figures 1A,B) is the 50-year-old father of patient 
1, with a medical history including aortic valve replacement at age 
29 and surgical and antibiotic treatment for a culture-negative, 
frontal-lobe brain abscess at age 33. He presented for the first time 
at our outpatient clinic at the age of 49 because of very severe 
C. albicans infection in the oral cavity and esophagus. At that 
time, he had already suffered from recurrent oral and esophageal 
fungal infections for years, for which he was treated with antifun-
gal therapies by his general physician. Microbiological analysis 
revealed a fluconazole-resistant C. albicans and treatment with 
posaconazole 400 mg once daily was initiated with prompt clinical 
improvement. Subsequently, prophylactic posaconazole 200 mg 
once daily has been prescribed. At the time of first analysis, also 
autoimmune hypothyroidism with positivity for antithyroglobu-
lin antibodies, ANA and lupus anticoagulant were detected. 
Peripheral blood total CD3+ T lymphocyte numbers [1.06 × 109/l 
(reference value: 0.7–2.1 × 109/l)], CD4+ T lymphocyte numbers 
[0.5 × 109/l (reference value: 0.3–1.4 × 109/l)], CD8+ T lympho-
cyte numbers [0.52 ×  109/l (reference value: 0.2–0.9 ×  109/l)], 
total CD19+ B lymphocyte numbers [0.35  ×  109/l (reference 
value: 0.1–0.4 ×  109/l)], and CD16+ CD56+ NK  cell numbers 
[0.16 × 109/l (reference value: 0.1–0.4 × 109/l)] were within the 
normal reference range. Immunoglobulin levels were also found 
within normal limits [IgG 12.9 g/l (reference value: 7.0–16.0 g/l), 
IgA 1.65  g/l (reference value: 0.76–3.91  g/l), and IgM 0.8  g/l 
(reference value: 0.45–2.30  g/l)]. The patient was negative for 
autoantibodies against IL-17A, IL-17F, and IL-22.
Sanger sequencing from all affected individuals in the family 
revealed a novel heterozygous signal transducer and activator 
of transcription 1 (STAT1) mutation in exon 22 at c.1957G>A, 
while genetic testing for mutations in 276 other known genes 
involved in primary immunodeficiency was negative (Table S1 in 
Supplementary Material). The nucleotide base change we identi-
fied has not been reported as single nucleotide polymorphism 
(the Human Gene Mutation Database, the National Center of 
Biotechnology Information, the ExAC database, the 1000G 
database, and the Ensembl database). The identified mutation 
results in replacement of a highly conserved valine at position 
653 (vertebrate Phylop100 score 3.798 and SiPhy score 19.656) 
(Figures  1C,D; Table S2 in Supplementary Material) into iso-
leucine [p.(Val653Ile)] within the Src homology 2 (SH2) domain 
of STAT1. The mutation is exposed on the outer surface of the 
molecule and within the vicinity of the phosphorylation site 
(Figure 1E; Video S1 in Supplementary Material). The Val653Ile 
mutation is predicted to hardly affect the overall structure of 
STAT1 and was predicted as “tolerated” by the Sort Intolerant 
From Tolerant algorithm (score 0.58). However, Val653Ile 
was predicted as “possibly damaging” by the Polymorphism 
Phenotyping v2 (PolyPhen-2, score 0.919), the mutation was 
speculated as “disease causing” from the Mutation Taster and was 
scaled in Combined Annotation Dependent Depletion algorithm 
with a score of 14.99, which suggests potential deleteriousness.
To evaluate the immunological phenotype associated with 
this mutation, STAT1 phosphorylation was studied by flow 
cytometry of fresh whole blood samples from patient 1 and an 
age-gender-race-matched healthy control. After stimulation 
with interferon (IFN)-α (104  IU/ml; PeproTech, London, UK), 
IFN-β (103  IU/ml; tebu-bio, Le-Perray-en-Yvelines, France), 
IFN-γ (105 IU/ml; R&D systems, Abingdon, UK) for 30 min, or 
IL-6 (100 ng/ml; R&D systems) for 15 min, cells were fixed and 
permeabilized with permeabilizing reagent (Phospho-Epitopes 
Exposure kit; Beckman Coulter). All samples were stained 
with CD3 (APC-conjugated antihuman CD3; BD Biosciences, 
CA, USA) and Fluor® 488-conjugated phospho-STAT1 Tyr701 
antibodies (Cell Signaling Technology, MA, USA). The levels 
of STAT1 phosphorylation in the CD3+ T  lymphocytes from 
the patient were higher than the levels observed in the healthy 
control after stimulation with IFNs (Figure 2A) or IL-6 (data not 
shown). To study the kinetics of STAT1 phosphorylation in more 
detail, time-course stimulation experiments were performed 
with fresh whole blood samples from patients 1 and 2 along with 
age-gender-race-matched healthy controls. The patients clearly 
displayed higher levels of STAT1 phosphorylation, yet the phos-
phorylation levels of both the patients and controls normalized 
over time (Figure 2B).
Because we found a higher basal level of phosphorylated 
STAT1 (pSTAT1) in patient 1 (Figure S1 in Supplementary 
Material), we established T  lymphocyte cultures to reduce the 
FIguRe 2 | stat1 phosphorylation evaluated by intracellular staining flow cytometry after stimulation with IFN-α, IFN-β, or IFN-γ. (a) Histograms 
showing MFI of phosphorylated STAT1 (pSTAT1) in CD3+ T lymphocytes (in fresh whole blood) of patient P1 and healthy control (HC1) after stimulation with IFN-α, 
IFN-β or IFN-γ for 30 min. (B) Kinetics of STAT1 phosphorylation in CD3+ T lymphocytes (in fresh whole blood) of the two patients and two healthy controls after 
stimulation with IFN-α, IFN-β, or IFN-γ. (C) Kinetics of STAT1 phosphorylation in T lymphocyte cultures from both patients and healthy controls. HC, healthy control; 
P, patient; US, unstimulated; MFI, mean fluorescence intensity.
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confounding effects of exposure of both patients to different 
pathogens and therapies. Long-term T lymphocyte cultures were 
expanded from peripheral blood mononuclear cells (PBMC) of 
both patients and two age-gender-race-matched healthy controls 
in RPMI-1640 medium (Lonza, Basel, Switzerland), containing 
10% heat inactivated human serum and antibiotics (2% penicillin 
and streptomycin; Cambrex BioWhittaker, Verviers, Belgium) in 
the presence of Phytohemagglutinin (1  μg/ml; Sigma-Aldrich, 
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MO, USA), IL-2 (25 IU/ml; Novartis, Basel, Switzerland), IL-15 
(12.5  ng/ml; BioLegend, CA, USA), and γ-irradiated (40  Gy) 
allogeneic PBMC and EBV-negative B lymphocytes. After 
2 weeks of culturing, T lymphocyte cultures (purity>90%) from 
both patients and healthy controls were analyzed for STAT1 
phosphorylation in a manner similar to the whole blood samples. 
IFN stimulation resulted in higher generation of pSTAT1 in 
the T  lymphocyte cultures from patients compared to healthy 
controls (Figure 2C). Stimulation of T lymphocyte cultures with 
IL-6 (100 ng/ml) yielded comparable results on pSTAT1 as IFN-γ 
(data not shown). T lymphocytes from the patients and healthy 
controls displayed similar levels of total STAT1 protein [deter-
mined by flow cytometry using a PE-conjugated STAT1 antibody 
(BD Biosciences; data not shown)]. STAT3 phosphorylation was 
also evaluated after stimulation with IL-6 (100 ng/ml) or IL-21 
(200  ng/ml; Life Technologies, MA, USA) but did not differ 
between patients and healthy controls (data not shown).
To assess the effect of the STAT1 mutation on cytokine 
production, PBMC of both patients and five race-matched 
healthy controls were freshly prepared and stimulated with 
heat-killed C. albicans [heat-killed Candida albicans (HKCA): 
106 cells]. Supernatants were collected, and levels of cytokines 
were measured by enzyme-linked immunosorbent assay (R&D 
systems). Cells were also stimulated with phorbol 12-myristate 
13-acetate (PMA) (81 nM) and ionomycin (I) (1.3 μM; eBiosci-
ence, CA, USA) as positive control. PBMC from both patients 
produced IL-6 and IL-1β levels comparable to that of healthy 
controls, while PBMC from patient 1 did not produce IFN-γ 
when stimulated with HKCA (Figure 3A). In contrast to PBMC 
from healthy controls, PBMC from the patients hardly increased 
IL-17A, IL-17F, and IL-22 production upon stimulation with 
PMA-I or HKCA (Figure 3A). STAT1 downstream target genes 
were also measured in T  lymphocyte cultures. Due to limited 
T lymphocyte numbers in these cultures, only one time-point of 
stimulation (24 h) with three different stimuli [IFN-γ (105 IU/
ml), IL-6 (100  ng/ml), and IL-27 (200  ng/ml; R&D systems)] 
was examined. CXCL9, CXCL10, and CD274 (PD-L1) mRNA 
expression levels were determined by real-time quantitative 
Taqman PCR in each sample on the basis of six replicates. 
Strikingly high mRNA levels were observed after IL-27 activa-
tion (P < 0.001) (Figure 3B).
BaCKgRouND
Chronic and/or recurrent fungal infections may be predomi-
nant manifestations in primary immunodeficiencies, especially 
in inherited T  lymphocyte defects. Various syndromes have 
been identified that present with recurrent fungal infections, for 
example, autosomal dominant (AD) hyper-immunoglobulin 
E syndrome, autosomal recessive autoimmune polyendocrine 
syndrome type I, and Mendelian susceptibility to mycobacterial 
diseases. AD-CMC is a rare and severe immunodeficiency that 
presents with severe mucocutaneous fungal infections, autoim-
mune phenomena, cerebral aneurysms and increased risk of 
oropharyngeal, and esophageal cancer (2–4). In the last decade, 
various heterozygous gain-of-function (GOF) mutations in 
STAT1 were found to be responsible for AD-CMC. So far, GOF 
mutations were described in the coiled-coil domain and the 
DNA-binding domain of STAT1, and in the past year, the GOF 
mutations c.1885C>T (p.H629Y) and c.1973G>A (p.N658S) 
involving the SH2 domain were described (5–7). Chronic and/
or recurrent mucocutaneous fungal infections with predomi-
nantly C. albicans are the major infectious complications in 
patients with STAT1 GOF mutations and generally arise in 
infancy or childhood. However, more than half of the patients 
encounter bacterial infections, with lower respiratory tract 
infections most frequently observed. Cutaneous viral infections 
are also described in about one third of patients (6,  8). In 
addition, many patients with GOF mutations in STAT1 develop 
autoimmune manifestations. Autoimmune thyroid disease is 
reported in 22% of patients. Cerebral aneurysms and cancers 
are among the most severe complications that are found more 
frequently and at younger age in these patients when compared 
to the general population (6, 8).
DIsCussIoN
The mutation identified in our patients is located in the STAT1 
SH2 domain resulting in recurrent mucocutaneous C. albicans 
infections, which is one of the clinical hallmarks of CMC. The 
other two family members who carry the same STAT1 mutation 
but were not included in this study also suffered from recurrent 
mucocutaneous candidiasis (Figure  1B). In addition to fungal 
infections, patient 1 showed an atypical susceptibility to a wide 
range of pathogens, as she experienced S. haemolyticus jaw abscess, 
S. aureus pneumonia, and CMV pneumonia. Lower respiratory 
tract bacterial infections can be found in about half of patients 
with STAT1 GOF mutations. However, based on previous reports, 
CMV pneumonia was described in only 1% of patients. Patient 2 
also encountered an intracranial abscess for which surgical and 
antibiotic treatments were required. Although the pathogenic 
microorganism could not be isolated, invasive deep-seated 
abscesses are uncommon for patients with STAT1 GOF mutations 
(6). Apart from CMC, atypical features of infections including 
invasive bacterial infections were also described in other patients 
carrying a STAT1 GOF mutation in the SH2 domain (5–7). Both 
patients 1 and 2 enrolled in this study developed a variety of 
autoimmune phenomena that were displayed in both clinical and 
laboratory analyses.
In response to various kinds of infections, STAT1 receives sig-
nals from the cell surface receptors and is subsequently phospho-
rylated at Tyr701. The SH2 domain carries the pTyr701-binding 
site and accordingly plays an important role in forming a firm 
cross-linkage dimerization between each STAT1 monomer. The 
dimers then accumulate in the nucleus, inducing transcription of 
genes (9). The mutation here described within the SH2 domain 
of STAT1 results in enhancement of STAT1 phosphorylation both 
upon stimulation with IFN-α/β and IFN-γ, despite the suggestion 
that the SH2 domain may not necessarily be required for STAT1 
activation by IFN-α/β (10). Moreover, this mutation may possibly 
affect molecule dimerization due to its specific location within the 
STAT1 molecule.
We performed STAT phosphorylation analysis of both 
patients by flow cytometry, which revealed enhancement of 
FIguRe 3 | (a) Dot plots depicting cytokine production in supernatant from peripheral blood mononuclear cells (PBMC) from both patients and healthy controls 
(n = 5) after stimulation of 106 PBMC with PMA-ionomycin (PMA+I) or heat-killed C. albicans (HKCA). Every symbol indicates an individual. US, unstimulated. 
(B) T lymphocyte cultures were stimulated for 24 h with IFN-γ, IL-27, or IL-6 and mRNA expression levels of CXCL9, CXCL10, and CD274 (PD-L1) were determined by 
real-time quantitative Taqman PCR. Data were normalized to the housekeeping gene, ABL. *P < 0.05, **P < 0.01, ***P < 0.001 when compared with healthy controls.
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STAT1 phosphorylation, while total STAT1 protein was equally 
measured in T  lymphocytes of both patients and healthy con-
trols. After stimulation with cytokines, STAT1 phosphorylation 
in the T  lymphocytes of both patients reached higher levels 
compared to the healthy controls. In contrast to previous reports 
studying mutations in other STAT1 domains (11–13), we found 
no clear prolonged STAT1 phosphorylation in the T  lympho-
cytes from the patients. The difference in the mutated domain 
of STAT1 could possibly be the cause of different phosphoryla-
tion characteristics. Apart from elevated pSTAT1 induction, we 
also noticed a higher basal pSTAT1 level in peripheral blood 
T lymphocytes from patient 1. Stimulation of fresh whole blood 
from patient 2 yielded comparable results, although this patient 
showed no elevated basal level of pSTAT1 when compared to 
healthy controls. However, after re-evaluation in established 
T  lymphocyte cultures, the elevated basal pSTAT1 level previ-
ously noted in the whole blood analysis of patient 1 disappeared. 
Due to the fact that patient 2 received prophylactic antifungal 
therapy while patient 1 did not at the time of analysis, recurrent 
exposure of patient 1 to Candida antigens could have caused the 
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elevated basal STAT1 phosphorylation we observed in her whole 
blood analysis. Because dysregulation of STAT3 has also been 
associated with CMC, we evaluated STAT3 phosphorylation as 
well, but this was comparable between the patients and healthy 
controls.
Th17-derived cytokines are crucial in fungal defense 
mechanisms (14, 15), and therefore, we examined the cytokine 
production capacity of PBMC of both patients as well as healthy 
controls upon activation with HKCA. A remarkable impairment 
in IL-17A, IL-17F, and IL-22 production was found in the 
patients. In order to further examine the consequence of this 
novel STAT1 SH2 domain mutation, STAT1 downstream target 
genes were assessed. T  lymphocyte cultures from both patients 
and healthy controls were stimulated with IFN-γ, IL-6, and 
IL-27. Significantly higher mRNA levels of STAT1 downstream 
target genes were found in both patients, especially upon IL-27 
activation, including CD274 (PD-L1). Overexpression of PD-L1 
was previously observed in naïve T lymphocytes of patients with 
STAT1 GOF mutation, and cytokine-induced PD-L1 expression 
in T  lymphocytes was found to hamper Th17 induction (16, 
17). Our data suggest that disturbed Th17 differentiation and 
associated cytokine production most likely underlies the clinical 
picture of CMC in the patients described here.
Since curative treatment is still unavailable, most of the 
patients with STAT1 GOF mutations receive prolonged sys-
temic antimicrobial medications to control clinical symptoms 
of recurrent fungal infections and other infections. Similar to 
patient 2, about 40% of the patients who require long-term 
antifungal treatment, eventually develop therapy resistance (6). 
Immunotherapies or immunosuppressive therapies are consid-
ered in some patients, although the effectiveness still needs to be 
evaluated in more detail (18). Surprisingly, novel therapies, like 
JAK1/2 inhibitors, showed not only the potency to suppress the 
enhanced STAT1 phosphorylation in CD4+ T lymphocytes but 
may also improve clinical outcome in both immunodeficiency 
and autoimmunity features (13, 19). These drugs could be poten-
tial future candidates for the treatment of patients with CMC 
with STAT1 GOF mutations.
CoNCLuDINg ReMaRKs
The novel Val653Ile mutation, located in the SH2 domain of 
STAT1 found in this family does not clearly result in an impaired 
STAT1 dephosphorylation rate, as was found in patients with GOF 
mutations in the other domains. However, significantly enhanced 
STAT1 phosphorylation in these patients results in higher expres-
sion of the STAT1 target genes CXCL9, CXCL10, and CD274 (PD-
L1). Moreover, this mutation is associated with the impairment of 
immune cells to produce IL-17A, IL-17F, and IL-22. The clinical 
symptoms of CMC could, therefore, be explained by diminished 
Th17 responses that are crucial for confronting fungal antigens.
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